Immunomedics (NASDAQ:IMMU) was upgraded by stock analysts at TheStreet from a “d” rating to a “c-” rating in a research report issued on Friday.

Other research analysts have also issued research reports about the company. Zacks Investment Research lowered Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. ValuEngine downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Finally, Jefferies Group lifted their price target on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.00.

Shares of Immunomedics (IMMU) opened at $15.13 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20. The company has a market capitalization of $2,504.99, a PE ratio of -7.49 and a beta of 1.50. Immunomedics has a twelve month low of $4.73 and a twelve month high of $18.93.

In other Immunomedics news, insider Behzad Aghazadeh acquired 1,325,000 shares of Immunomedics stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $10.47 per share, with a total value of $13,872,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian A. Markison sold 8,390 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the completion of the transaction, the director now directly owns 99,178 shares of the company’s stock, valued at approximately $1,179,226.42. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Immunomedics by 8.8% in the fourth quarter. BlackRock Inc. now owns 9,064,259 shares of the biopharmaceutical company’s stock worth $146,478,000 after buying an additional 736,608 shares in the last quarter. FMR LLC raised its stake in Immunomedics by 260.6% in the second quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock worth $48,537,000 after buying an additional 3,972,388 shares in the last quarter. State Street Corp raised its stake in Immunomedics by 37.2% in the second quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock worth $42,549,000 after buying an additional 1,305,298 shares in the last quarter. Vanguard Group Inc. raised its stake in Immunomedics by 2.4% in the second quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock worth $39,930,000 after buying an additional 105,558 shares in the last quarter. Finally, NEA Management Company LLC bought a new position in Immunomedics in the third quarter worth approximately $38,762,000. 75.95% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/thestreet-upgrades-immunomedics-immu-to-c.html.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.